Anifrolumab Asian PhIII Efficacy Study for Systemic Lupus Erythematosus (SLE)
| Condition | Active Systemic Lupus Erythematosus |
|---|---|
| Phase | Phase 3 |
| Sponsor | AstraZeneca |
| Status | Completed |
| Enrollment | 277 participants |
| Interventions | Anifrolumab |
| Start date | Sep 13, 2021 |
| Completion date | Apr 7, 2025 |
| Results posted | May 20, 2026 |
Summary
The purpose of this study is to evaluate the efficacy and safety of an intravenous treatment regimen of anifrolumab versus placebo in Asian participants with active systemic lupus erythematosus (SLE).
Difference in Proportion of Participants Who Are Responders Between Anifrolumab and Placebo
| Anifrolumab 300mg | 84 Participants |
|---|---|
| Placebo | 46 Participants |
| p-value | >0.999 |
|---|---|
| Rate difference (%) | 28.4 |
Open in BENITIONS View on ClinicalTrials.gov
Other trials for this condition
- Clinical Study to Investigate the Biological Activity, Safety, Tolerability, and Pharmacok — Viatris Innovation GmbH
- Efficacy and Safety of Four Doses of Cenerimod Compared to Placebo in Adult Subjects With — Viatris Innovation GmbH
- A Study to Evaluate the Efficacy and Safety of Obinutuzumab in Participants With ISN/RPS 2 — Hoffmann-La Roche
- Peer i-Coaching for Activated Self-Management Optimization in Adolescents and Young Adults — Duke University
- Reducing Disparities in Medication Adherence in SLE — Duke University
- Using the Cholinergic Anti-Inflammatory Pathway to Treat Systemic Lupus Musculoskeletal Pa — Northwell Health